Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

78.64EUR
23 Apr 2018
Change (% chg)

€-0.28 (-0.35%)
Prev Close
€78.92
Open
€79.14
Day's High
€79.14
Day's Low
€78.08
Volume
244,012
Avg. Vol
468,186
52-wk High
€98.82
52-wk Low
€61.88

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

Beta: 1.20
Market Cap(Mil.): €4,062.53
Shares Outstanding(Mil.): 51.23
Dividend: --
Yield (%): --

Financials

  GLPG.AS Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -2.31 -- --
ROI: -11.05 -0.74 13.21
ROE: -13.07 -2.80 15.01

BRIEF-Galapagos NV Creates New Warrant Plan

* BOARD OF DIRECTORS CREATED 1.6 MILLION WARRANTS UNDER NEW WARRANT PLANS

Apr 19 2018

BRIEF-Galapagos Announces ISABELA Phase 3 Program In IPF

* ANNOUNCES THE DESIGN OF A WORLDWIDE PHASE 3 PROGRAM, TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

Apr 12 2018

BRIEF-Galapagos Announces Isabela Phase 3 Program In IPF

* ANNOUNCES DESIGN OF A WORLDWIDE PHASE 3 PROGRAM TO EVALUATE GLPG1690 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

Apr 12 2018

BRIEF-Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros

* REPORTED ON THURSDAY FY NET LOSS OF €115.7 MILLION, COMPARED TO NET PROFIT OF €54.0 MILLION IN 2016

Feb 23 2018

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

Feb 19 2018

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

Feb 19 2018

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

Jan 08 2018

BRIEF-Galapagos Reports Preliminary Topline Results In Osteoarthritis Study

* REPORTED ON SUNDAY, POSITIVE PRELIMINARY TOPLINE RESULTS WITH A PHASE 1B STUDY IN OSTEOARTHRITIS (OA) PATIENTS IN THE UNITED STATES

Jan 08 2018

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

Dec 15 2017

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

Dec 11 2017

Earnings vs. Estimates